Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells

Neoplasia

Volumn 9, Issue 12, 2007, Pages 1078-1090

  Sarrabayrouse, Guillaume ^a,b   Synaeve, Cindy ^a,b   Leveque, Kevin ^a,b   Favre, Gilles ^a,b,c   Tilkin Mariamé, Anne Françoise ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Apoptosis; FasL; Melanoma; RhoA; Statins

Indexed keywords

ATORVASTATIN; EXOTOXIN; FAS LIGAND; GGTI 298; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; IN VITRO STUDY; LYMPHOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 37149012084     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07727     Document Type: Article

References (54)

1. Suda T, Takahashi T, Golstein P, and Nagata S (1993). Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178.
2. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, and Krammer PH (1989). Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305.
3. Los M, Wesselborg S, and Schulze-Osthoff K (1999). The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 10, 629-639.
4. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, and Nagata S (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243.
5. Yonehara S, Ishii A, and Yonehara M (1989). A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169, 1747-1756.
6. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, and Moller P (1993). Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69, 415-429.
7. Brunner T, Wasem C, Torgler R, Cima I, Jakob S, and Corazza N (2003). Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 15, 167-176.
8. Boise LH, Minn AJ, and Thompson CB (1995). Receptors that regulate T-cell susceptibility to apoptotic cell death. Ann N Y Acad Sci 766, 70-80.
9. Lee J, Richburg JH, Younkin SC, and Boekelheide K (1997). The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 138, 2081-2088.
10. Ivanov VN, Bhoumik A, and Ronai Z (2003). Death receptors and melanoma resistance to apoptosis. Oncogene 22, 3152-3161.
11. Gajewski TF (2006). Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 12, 2326s-2330s.
12. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, et al. (1996). Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
13. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161, 1220-1230.
14. Wada A, Tada Y, Kawamura K, Takiguchi Y, Tatsumi K, Kuriyama T, Takenouchi T, O-Wang J, and Tagawa M (2007). The effects of FasL on inflammation and tumor survival are dependent on its expression levels. Cancer Gene Ther 14, 262-267.
15. Tada Y, O-Wang J, Wada A, Takiguchi Y, Tatsumi K, Kuriyama T, Sakiyama S, and Tagawa M (2003). Fas ligand - expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity. Cancer Gene Ther 10, 134-140.
16. Chan KK, Oza AM, and Siu LL (2003). The statins as anticancer agents. Clin Cancer Res 9, 10-19.
17. Jakobisiak M and Golab J (2003). Potential antitumor effects of statins (Review). Int J Oncol 23, 1055-1069.
18. Tilkin-Mariame AF, Cormary C, Ferro N, Sarrabayrouse G, Lajoie-Mazenc I, Faye JC, and Favre G (2005). Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC class I and costimulatory molecule expression. FASEB J 19, 1513-1515.
19. Ryan AE, Lane S, Shanahan F, O'Connell J, and Houston A (2006). Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. J Carcinog 5, 5.
20. Hall A (1998). Rho GTPases and the actin cytoskeleton. Science 279, 509-514.
21. 1 phase of the cell cycle. Oncogene 8, 1449-1455.
22. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, and Moses HL (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12, 27-36.
23. Worthylake RA, Lemoine S, Watson JM, and Burridge K (2001). RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 154, 147-160.
24. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, and Lacal JC (1997). Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 11, 463-475.
25. Mellor H, Flynn P, Nobes CD, Hall A, and Parker PJ (1998). PRK1 is targeted to endosomes by the small GTPase, RhoB. J Biol Chem 273, 4811-4814.
26. Coleman ML and Olson MF (2002). Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 9, 493-504.
27. Brenner B, Koppenhoefer U, Weinstock C, Linderkamp O, Lang F, and Gulbins E (1997). Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem 272, 22173-22181.
28. Esteve P, del Peso L, and Lacal JC (1995). Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis. Oncogene 11, 2657-2665.
29. Hori Y, Kikuchi A, Isomura M, Katayama M, Miura Y, Fujioka H, Kaibuchi K, and Takai Y (1991). Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene 6, 515-522.
30. Vindelov LL and Christensen IJ (1990). A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 11, 753-770.
31. Simpson KJ, Dugan AS, and Mercurio AM (2004). Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 64, 8694-8701.
32. Ren XD and Schwartz MA (2000). Determination of GTP loading on Rho. Methods Enzymol 325, 264-272.
33. Gampel A and Mellor H (2002). Small interfering RNAs as a tool to assign Rho GTPase exchange-factor function in vivo. Biochem J 366, 393-398.
34. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, et al. (2001). Evaluation of farnesyl:protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res 61, 8758-8768.
35. Adnane J, Bizouarn FA, Qian Y, Hamilton AD, and Sebti SM (1998). p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol 18, 6962-6970.
36. Kusama T, Mukai M, Tatsuta M, Nakamura H, and Inoue M (2006). Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. Int J Oncol 29, 217-223.
37. Aktories K and Hall A (1989). Botulinum ADP-ribosyltransferase C3: a new tool to study low molecular weight GTP-binding proteins. Trends Pharmacol Sci 10, 415-418.
38. Fleuren GJ, Gorter A, Kuppen PJ, Litvinov S, and Warnaar SO (1995). Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 145, 91-122.
39. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, and Feldman M (1991). Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51, 6372-6380.
40. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, and Bennink JR (1993). Identification of human cancers deficient in antigen processing. J Exp Med 177, 265-272.
41. Sulitzeanu D (1993). Immunosuppressive factors in human cancer. Adv Cancer Res 60, 247-267.
42. O'Connell J, O'Sullivan GC, Collins JK, and Shanahan F (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184, 1075-1082.
43. Walker PR, Saas P, and Dietrich PY (1997). Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 158, 4521-4524.
44. Radfar S, Martin H, and Tilkin-Mariame AF (2000). Tumor escape mechanism involving Fas and Fas-L molecules in human colorectal tumors. Gastroenterol Clin Biol 24, 1191-1196.
45. Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, Lorz C, Diaz C, Hernandez G, and Egido J (2003). 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 108, 1506-1513.
46. Embade N, Valeron PF, Aznar S, Lopez-Collazo E, and Lacal JC (2000). Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production. Mol Biol Cell 11, 4347-4358.
47. Bossi G and Griffiths GM (1999). Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 5, 90-96.
48. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, and Mor G (2003). Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 63, 5573-5581.
49. Nishimura Y, Itoh K, Yoshioka K, Uehata M, and Himeno M (2000). Small guanosine triphosphatase Rho/Rho associated kinase as a novel regulator of intracellular redistribution of lysosomes in invasive tumor cells. Cell Tissue Res 301 (31), 341-351.
50. Martinez-Lorenzo MJ, Anel A, Alava MA, Pineiro A, Naval J, Lasierra P, and Larrad L (2004). The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 295, 315-329.
51. Hetz CA, Hunn M, Rojas P, Torres V, Leyton L, and Quest AF (2002). Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase. J Cell Sci 115, 4671-4683.
52. Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL, and Wang YH (2005). Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol 11, 3632-3635.
53. Ryan AE, Shanahan F, O'Connell J, and Houston AM (2005). Addressing the "Fas counterattack" controversy: blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 65, 9817-9823.
54. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE, and Geilen CC (2003). CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22, 9131-9141.